Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf Gets Unanimous Committee Vote Supporting FDA Commissioner Bid

This article was originally published in Clinica

Executive Summary

After being thoroughly questioned, Robert Califf won a unanimous vote in support of his bid to become the next FDA commissioner from the Senate Health, Education, Labor and Pensions Committee on Jan. 12. Califf, who currently serves as FDA's deputy commissioner for medical products and tobacco, still requires full Senate approval and is likely to find some challenges there.

You may also be interested in...



Califf Clears First Senate Hurdle, But Could FDA’s Abortion Pill Access Decision Be A Headache?

Robert Califf’s nomination to be the next US FDA commissioner squeaked out of the Senate health committee, but a significant number of Republicans are against his confirmation over the agency’s recent decisions on abortion drugs.

Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’

Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.

Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel